Literature DB >> 11495619

Invasive meningococcal disease in adolescents and young adults.

L H Harrison1, M A Pass, A B Mendelsohn, M Egri, N E Rosenstein, A Bustamante, J Razeq, J C Roche.   

Abstract

CONTEXT: Incidence of invasive meningococcal disease has increased recently in persons aged 15 through 24 years.
OBJECTIVE: To characterize meningococcal infection in adolescents and young adults in Maryland during the 1990s. DESIGN AND
SETTING: Population-based surveillance study for meningococcal disease from January 1, 1990, through December 31, 1999, in Maryland. PATIENTS: Maryland residents diagnosed as having invasive meningococcal disease. MAIN OUTCOME MEASURE: Invasive meningococcal infection.
RESULTS: Of 295 total cases, 71 (24.1%) occurred among persons aged 15 through 24 years. Sixteen (22.5%) of these cases were fatal. The annual incidence rate increased from 0.9 to 2.1 cases per 100 000 among 15 through 24 year olds (P =.01). The proportion of all disease increased from 16.0% to 28.9% (P =.03). The incidence and proportion of cases subsequently decreased to 1.0 and 16.4% in 1998 through 1999, respectively. Infection in 15 through 24 year olds was more likely to be fatal than infection in those younger than age 15 years (22.5% vs 4.6%; P =.001). Infection in 15 through 24 year olds, compared with those aged 25 years or older, was more likely to be associated with male sex (66.2% vs 34.8%; P<.001) and serogroup C infection (46.9% vs 20.2%; P<.001), respectively. Infections were potentially preventable with the licensed meningococcal vaccine in 82.8% of 15 through 24 year olds, 68.1% of those younger than 15 years, and 76.8% of adults aged 25 years or older.
CONCLUSIONS: Incidence of meningococcal infection in 15 through 24 year olds in Maryland increased and then declined during the 1990s. Infection in this age group was associated with an unusually high case-fatality ratio, and the vast majority of cases were potentially vaccine preventable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495619     DOI: 10.1001/jama.286.6.694

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  35 in total

1.  Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.

Authors:  Ana Cristina C Frota; Lucimar G Milagres; Lee H Harrison; Bianca Ferreira; Daniela Menna Barreto; Gisele S Pereira; Aline C Cruz; Wania Pereira-Manfro; Ricardo Hugo de Oliveira; Thalita F Abreu; Cristina B Hofer
Journal:  Pediatr Infect Dis J       Date:  2015-05       Impact factor: 2.129

2.  Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students.

Authors:  J D Holmes; D Martin; C Ramsay; E Ypma; P Oster
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

3.  Post-marketing study on the safety of a meningococcal group A, C bivalent polysaccharide conjugate vaccine.

Authors:  Chuanxi Fu; Guihua Huang; Min Cui; Ming Wang
Journal:  Hum Vaccin Immunother       Date:  2013-09-06       Impact factor: 3.452

Review 4.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

5.  Epidemiological features of invasive Kingella kingae infections and respiratory carriage of the organism.

Authors:  Pablo Yagupsky; Nechama Peled; Orna Katz
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 6.  Epidemiological profile of meningococcal disease in the United States.

Authors:  Lee H Harrison
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

7.  Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.

Authors:  Socorro Lupisan; Kriengsak Limkittikul; Nestor Sosa; Pornthep Chanthavanich; Véronique Bianco; Yaela Baine; Marie Van der Wielen; Jacqueline M Miller
Journal:  Clin Vaccine Immunol       Date:  2013-07-24

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  College and university compliance with a required meningococcal vaccination law.

Authors:  Amanda D Castel; Greg Reed; Marsha G Davenport; Lee H Harrison; David Blythe
Journal:  J Am Coll Health       Date:  2007 Sep-Oct

10.  Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.

Authors:  Keith S Reisinger; Roger Baxter; Stanley L Block; Jina Shah; Lisa Bedell; Peter M Dull
Journal:  Clin Vaccine Immunol       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.